person · Reporting owner
Schaeffer Orlov S Nicole
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| INSMED IncINSM · Entity 3174 | Chief People Strategy Officer | January 02, 2026 | January 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
INSMED Inc
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 41,754 |
Ending reported balance
After 2026-01-02 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2026-01-02 · Grant · Acquired 5,293 · Balance 41,754 F1: Represents Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's Amended and Restated 2019 Incentive Plan, as amended. The RSUs vest as follows: 25% on the first day of the first month following the first anniversary of the date of grant (the Initial Vesting Date) and 25% on each anniversary of the Initial Vesting Date until fully vested. F2: Each RSU was granted on January 2, 2026 for no consideration. Row 2 · 2026-01-02 · Exercise / conversion · Acquired 87,290 · Balance 129,044 F3: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 29, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Row 3 · 2026-01-02 · Sale · Disposed 31,030 · Balance 98,014 F3: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 29, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4: This is the weighted average sales price representing 31,030 shares sold at prices ranging from $173.67 to $174.66 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Row 4 · 2026-01-02 · Sale · Disposed 34,103 · Balance 63,911 F3: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 29, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5: This is the weighted average sales price representing 34,103 shares sold at prices ranging from $174.67 to $175.65 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Row 5 · 2026-01-02 · Sale · Disposed 12,832 · Balance 51,079 F3: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 29, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F6: This is the weighted average sales price representing 12,832 shares sold at prices ranging from $175.67 to $176.62 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Row 6 · 2026-01-02 · Sale · Disposed 9,125 · Balance 41,954 F3: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 29, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F7: This is the weighted average sales price representing 9,125 shares sold at prices ranging from $176.68 to $177.67 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Row 7 · 2026-01-02 · Sale · Disposed 200 · Balance 41,754 F3: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 29, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F8: This is the weighted average sales price representing 200 shares sold at prices ranging from $177.72 to $177.84 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $177.12 · Expires 2036-01-02 | Direct | 27,600 |
Reported balance
After 2026-01-02 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-01-02 · Grant · Acquired 27,600 · Balance 27,600 F9: These stock options were granted under the Company's Amended and Restated 2019 Incentive Plan, as amended. The options become exercisable based on the following vesting schedule: 25% vest on the Initial Vesting Date and an additional 12.5% vest every six months thereafter until fully vested. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.91 · Expires 2029-01-03 | Direct | 0 |
Reported balance
After 2026-01-02 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-01-02 · Exercise / conversion · Disposed 87,290 · Balance 0 F3: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 29, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F10: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's Amended and Restated 2019 Incentive Plan, as amended. The RSUs vest as follows: 25% on the first day of the first month following the first anniversary of the date of grant (the Initial Vesting Date) and 25% on each anniversary of the Initial Vesting Date until fully vested.
F2: Each RSU was granted on January 2, 2026 for no consideration.
F3: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on August 29, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F4: This is the weighted average sales price representing 31,030 shares sold at prices ranging from $173.67 to $174.66 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
F5: This is the weighted average sales price representing 34,103 shares sold at prices ranging from $174.67 to $175.65 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
F6: This is the weighted average sales price representing 12,832 shares sold at prices ranging from $175.67 to $176.62 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
F7: This is the weighted average sales price representing 9,125 shares sold at prices ranging from $176.68 to $177.67 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
F8: This is the weighted average sales price representing 200 shares sold at prices ranging from $177.72 to $177.84 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.
F9: These stock options were granted under the Company's Amended and Restated 2019 Incentive Plan, as amended. The options become exercisable based on the following vesting schedule: 25% vest on the Initial Vesting Date and an additional 12.5% vest every six months thereafter until fully vested.
F10: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 07, 2016 Filed Nov 9, 2016 21:31 UTC | INSMED Inc INSM · Entity 3174 | SaleCommon Stock | 37,500 | $11.78 | $441,750.00 |
DisclosureSEC source: 0001127430-16-000155 · edgar.xml · nonDerivative · entry 2 Schaeffer Orlov S Nicole · CIK 0001401017 · SVP, HR & Corp. Svcs. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price in column 4 is a weighted average price. The prices in these transactions range from $11.75 to $11.91. Read SEC document |
| November 07, 2016 Filed Nov 9, 2016 21:31 UTC | INSMED Inc INSM · Entity 3174 | Exercise / conversionCommon Stock | 37,500 | $6.96 | $261,000.00 |
DisclosureSEC source: 0001127430-16-000155 · edgar.xml · nonDerivative · entry 1 Schaeffer Orlov S Nicole · CIK 0001401017 · SVP, HR & Corp. Svcs. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.